Stoke Therapeutics (STOK) Property, Plant & Equipment (Net) Growth (1y) (2019 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Property, Plant & Equipment (Net) Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 24.71% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 12.77% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -99.85% |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | -5.07% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 1.70% |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 10.87% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 19.14% |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 44.45% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.45% |
| Mar 31, 2026 | -5.98% |
| Dec 31, 2025 | -19.52% |
| Sep 30, 2025 | -28.85% |
| Jun 30, 2025 | -29.92% |
| Mar 31, 2025 | -31.58% |
| Dec 31, 2024 | -32.87% |
| Sep 30, 2024 | -30.30% |
| Jun 30, 2024 | -26.30% |
| Mar 31, 2024 | -22.26% |
| Dec 31, 2023 | -12.76% |
| Sep 30, 2023 | -13.18% |
| Jun 30, 2023 | 10.29% |
| Mar 31, 2023 | 34.84% |
| Dec 31, 2022 | 61.27% |
| Sep 30, 2022 | 143.32% |
| Jun 30, 2022 | 103.47% |
| Mar 31, 2022 | 85.72% |
| Dec 31, 2021 | 54.73% |
| Sep 30, 2021 | 1.73% |